Voyager Therapeutics Inc. has expanded its Alzheimer’s disease (AD) pipeline with the addition of a wholly owned program that modulates the expression of apolipoprotein E (APOE). Using a proprietary intravenous-delivered, blood-brain barrier (BBB)-penetrant Tracer capsid, the product delivers a bifunctional payload.

Illimis Therapeutics Inc. raised ₩58 billion (US$42 million) in a series B financing round. The funds will support development of ILM-01, its lead bispecific fusion protein candidate, into preclinical development for Alzheimer’s disease by the second half of 2025, along with the company’s neuroimmunology portfolio.

Acumen Pharmaceuticals Inc. and JCR Pharmaceuticals Co. Ltd. have entered a collaboration, option and license agreement to develop a novel therapeutic candidate for the treatment of Alzheimer’s disease (AD).

Multiple sclerosis (MS) is a degenerative and inflammatory condition of the central nervous system (CNS) that impacts more than 2.5 million individuals globally. Interleukin-33 (IL-33) is an immunoregulatory cytokine that has shown a mild inhibitory effect on experimental autoimmune encephalomyelitis (EAE), which serves as a mouse model for MS. However, its clinical application is limited by unfavorable pharmacokinetics and associated toxicity.